Who is sponsoring NCT07103577?

NCT07103577 is sponsored by Hams Hamed Abdelrahman.

What drugs are being tested in NCT07103577?

Interventions in NCT07103577: Island osteoperiosteal flap, Conventional ridge splitting.

What condition does NCT07103577 study?

NCT07103577 studies Maxillary Alveolar Reconstruction, Virtual Surgical Planning.

Is NCT07103577 still recruiting?

NCT07103577 is currently completed. Last updated 5 August 2025.

Last reviewed 2025-08-05 · How we verify

NCT07103577

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Guided Island Osteoperiosteal Flap Versus Ridge Splitting for Anterior Atrophic Maxillary

Completed NA Last updated 5 August 2025

What this trial tests

NA trial testing Island osteoperiosteal flap in Maxillary Alveolar Reconstruction in 20 participants. Completed in 13 May 2025.

Timeline

5 November 2023

Primary endpoint
13 May 2025

13 May 2025

Quick facts

Lead sponsor	Hams Hamed Abdelrahman
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	5 November 2023
Primary completion	13 May 2025
Estimated completion	13 May 2025
Sites	1 location across Egypt

Drugs / interventions tested

Island osteoperiosteal flap
Conventional ridge splitting

Conditions studied

Maxillary Alveolar Reconstruction — all drugs for Maxillary Alveolar Reconstruction →
Virtual Surgical Planning — all drugs for Virtual Surgical Planning →

Sponsor

Hams Hamed Abdelrahman — full company profile →

Who can join

Adults 20 to 60, any sex, with Maxillary Alveolar Reconstruction or Virtual Surgical Planning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: After tooth extraction changes of the shape of the alveolar bone follows a predictable pattern, which proves to be challenging in restoring its form and function, especially in the esthetic zone. Autogenous grafts remain the gold standard because of their predictability. The island osteoperiosteal flap (I-flap) is introduced as a modified alveolar split bone grafting technique used to gain width, height and modify the facial or buccal bone plate position. Aim of the study: This study aims to evaluate in anterior atrophic maxillary ridge augmentation using guided unreflected island osteoperiosteal flap (I-Flap) approach with simultaneous implant placement and interpostional bone grafting in comparison to computer guided ridge splitting method.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of 3-Dimensional accuracy of guided implant placement using guided osteoperiosteal flap versus guided ridge splitting for atrophic maxillary augmentation (a randomized clinical trial).
Salem OAEH, Elmahlawy AS, Saber ME. · · 2025 · PMID 41350657 · DOI 10.1186/s12903-025-07364-6

Verify or expand the search:

Other Hams Hamed Abdelrahman trials

Trials by the same sponsor.

NCT07044882 — Hydrodynamic Piezoelectric Technique in Internal Sinus Lift · NA · not yet recruiting
NCT07082634 — Immediate Implant Placement Using the Socket Shield Technique in Maxillary Esthetic Zone · NA · not yet recruiting
NCT07044895 — Diode Laser Photocoagulation With Immediate Implant Placement · NA · not yet recruiting
NCT06759311 — Two Different Minimal Invasive Techniques in Caries Removal of Primary Teeth · NA · active not recruiting
NCT07103564 — The Effect of Local Melatonin Application Around Immediately Placed Implants in the Maxillary Premolar · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07103577 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hams Hamed Abdelrahman
Last refreshed: 5 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07103577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing